Related Experiment Video
Updated: Aug 6, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
Association of Elevated Platelets and C-Reactive Protein With Severe Disease and Poor Survival in Systemic Sclerosis
Brian S Lee1, Shufeng Li1, Srijana Davuluri1
1Stanford University, Stanford, California.
Insights
Elevated platelets and C-reactive protein (CRP) together indicate severe systemic sclerosis (SSc) with poor survival. This dual elevation signals a need for proactive management of SSc complications.
Area of Science:
- Rheumatology
- Immunology
- Clinical Medicine
Background:
- Elevated C-reactive protein (CRP) is linked to severe systemic sclerosis (SSc) and reduced survival.
- The prognostic significance of platelet levels in SSc remains less understood.
- This study investigates the combined impact of elevated platelets and CRP on SSc outcomes.
Purpose of the Study:
- To determine the association between elevated platelet levels, CRP levels, or both, and SSc disease severity.
- To evaluate the relationship between these biomarkers and SSc progression.
- To assess the impact of combined elevated platelets and CRP on SSc patient survival.
Main Methods:
- Retrospective analysis of 139 adult SSc patients from 1996-2022.
- Patients categorized into four groups based on first blood draw: normal/normal, normal platelet/elevated CRP, elevated platelet/normal CRP, and elevated platelet/elevated CRP.
- Cutoffs used: platelets ≥330,000/μL and CRP ≥6.0 mg/L.
Main Results:
- The elevated platelet/elevated CRP (EP/EC) group showed higher rates of Scl-70 antibodies, diffuse skin involvement, myocarditis, dysphagia, GAVE, joint contractures, and digital ulcers.
- EP/EC patients had the highest modified Rodnan skin scores.
- Median survival was significantly lower in the EP/EC group (9.6 years) compared to normal/normal (21.3 years), with a hazard ratio of 7.34.
Conclusions:
- Combined elevated platelet and CRP levels identify SSc patients with severe disease and poor prognosis.
- Patients with dual biomarker elevation may require intensified screening and treatment for complications.
- Isolated elevation of either platelets or CRP was associated with intermediate disease severity.
Objective:
Elevated C-reactive protein (CRP) levels in systemic sclerosis (SSc) have been linked with severe disease and worse survival, but the role of platelet levels remains unclear. This study examined whether elevated platelet levels, CRP levels, or both are associated with disease severity, progression, and survival in SSc.
Methods:
We performed a retrospective study of adult patients with SSc seen from 1996 to 2022. Using the first blood draw after symptom onset, patients were categorized into four groups using cutoffs of ≥330,000/μL for platelets and ≥6.0 mg/L for CRP: (1) normal platelet/normal CRP (NP/NC), (2) normal platelet/elevated CRP (NP/EC), (3) elevated platelet/normal CRP (EP/NC), (4) elevated platelet/elevated CRP (EP/EC).
Results:
One hundred and thirty-nine patients were included (84 NP/NC [60%], 33 NP/EC [24%], 10 EP/NC [7%], and 12 EP/EC [9%]). The EP/EC had the highest rates of Scl-70 antibody positivity, diffuse skin involvement, myocarditis/cardiomyopathy, dysphagia, gastric antral vascular ectasia, joint contractures, and digital ulcers (P < 0.05). NP/NC had the best baseline forced vital capacity, which remained stable over two years, though differences among groups over time were not significant. EP/EC had the highest modified Rodnan skin scores throughout the two-year period (P < 0.05). Median survival was lowest in the EP/EC group (9.6 years vs 21.3 years in NP/NC, P < 0.0001), with an adjusted hazard ratio of 7.34 (95% CI 2.40-22.41, Bonferroni-adjusted P = 0.0025). Patients with isolated CRP or platelet elevation demonstrated intermediate disease severity compared with the dual-elevation group.
Conclusion:
Elevated platelet levels in combination with elevated CRP levels identifies patients with SSc with severe disease and poor survival, who may warrant aggressive screening and treatment of complications.
More Related Videos
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Cardiomyopathy IV: Restrictive Cardiomyopathy

